Nexo Therapeutics
Robert van de Ven is a Senior Scientist at nexo therapeutics, with previous experience at Cyteir Therapeutics and LifeMine Therapeutics in similar roles. Robert holds a Doctor of Philosophy degree in Cancer Research & Molecular Cell Biology from Utrecht University, where Robert also completed their Master of Science in Biomedical Sciences and Bachelor of Science in Biology. Prior to their industry experience, Robert held positions at Harvard Medical School as a Postdoctoral Fellow and at UMC Utrecht as a PhD Student. Additionally, Robert was a Visiting Graduate Student at UCSF for a brief period.
Nexo Therapeutics
Nexo Therapeutics is a small molecule oncology company dedicated to the discovery and development of new drugs for cancer patients who currently lack meaningful therapies. Nexo combines covalent ligand discovery and chemical biology with expertise in cancer biology and medicinal chemistry to target fundamental drivers of cancer by innovative approaches. With facilities in Golden, CO and Watertown, MA, Nexo is led by Founder and CEO, Andrew Phillips, PhD. For more information, please visit www.nexotx.com.